Project Grant HT94252311028
Award Date
9/15/23
Completion Date
9/14/27
Dollars Obligated
$1.4M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
This $5,149,107 federal Project Grant award, granted by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the Fred Hutchinson Cancer Center's research to define human correlates of super-evasive disseminated tumor cells, investigate their pathological relevance, and explore methods to eradicate them. The research aims to transform healthcare for military service members and the broader public through innovative and impactful...
The federal Project Grant award, ID HT94252411040, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The $879,692 award, with a performance period from September 30, 2024 to September 29, 2027, supports the Fred Hutchinson Cancer Center's research on "Combinatorial Phenotype-Targeted Therapy to Overcome Mechanisms Driving Prostate Cancer Treatment Resistance." This innovative research project aims to develop novel...
This $1,927,373 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports the Fred Hutchinson Cancer Center in Seattle, Washington in the development of targeted therapies for metastatic prostate cancers classified by subtypes of DNA repair deficiency. The award period runs from February 15, 2025 to February 14, 2028. As a leading cancer research institution, the Fred Hutchinson Cancer Center will...
The federal Project Grant award of $1,578,836.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) in developing and exploiting a third-generation prostate cancer dependency map to identify cancer vulnerabilities and treatment targets. The award, which runs from August 1, 2024 to July 31, 2027, will enable the research organization to conduct innovative...
This $525,847 federal Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research by the Fred Hutchinson Cancer Center in Seattle, Washington. The grant funds research to define and exploit essential components of the androgen receptor program operative in castration-resistant prostate cancers. This 2-year award, effective from July 2025 to July 2027, will enable the cancer center to...
This $2,112,000 federal Project Grant award, funded by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420), supports research at the Fred Hutchinson Cancer Center (also known as the Seattle Cancer Care Alliance) to investigate the prevention of liver metastasis by defining regulators of tumor dormancy and how to reverse their disruption. The performance period for this grant runs from July 1, 2025 to June 30, 2029. As a leading...
The University of Pittsburgh was awarded a $954,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from May 2023 to May 2026 aimed at epigenetic reprogramming to target senescent ovarian cancer cells and overcome therapeutic resistance. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
This Project Grant award for $699,750 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to the University of Washington aims to support the discovery and characterization of tissue-specific regulatory mutations that predispose to ovarian cancer. The award will fund research activities over a 3-year period from April 2024 to March 2027. As a leading research university, the University of Washington has extensive experience managing federal grants and...
This $816,676 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports a study by the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) to conduct a multiomic evaluation of ovarian cancer responses to heated intraperitoneal chemotherapy (HIPEC). The 3-year study, with a period of performance from September 30, 2024 to August 31, 2027, aims to advance understanding of how HIPEC...
The Defense Health Agency awarded a $528,000 Project Grant to the Fred Hutchinson Cancer Center, doing business as the Seattle Cancer Care Alliance, to assess the landscape of cell surface targets in metastatic prostate cancer. This 2-year grant, which began on April 15, 2024, is funded through the Military Medical Research and Development program (CFDA 12.420). The project aims to advance biomedical research on innovative therapeutic approaches for cancer, in line with the program's goals of...